Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Portfolio Pulse from
Inventiva announced that results from its trial evaluating lanifibranor with empagliflozin for MASH treatment will be presented at the EASL SLD Summit 2025.
January 22, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva's trial results on lanifibranor in combination with empagliflozin for MASH will be presented at a major medical summit, potentially increasing visibility and investor interest.
The selection of Inventiva's trial results for presentation at a prestigious summit suggests positive outcomes and could enhance the company's reputation and investor interest. This may lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90